Acurx: 'Positive Partial Comparative Data' for Ibezapolstat from Phase 2b C. diff. Trial

 

• Ibezapolstat outperformed vancomycin showing eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 treated patients (94%), versus vancomycin which had eradication of C. difficile in 10 of 14 treated patients (71%).
• Ibezapolstat, but not vancomycin, consistently preserved and allowed regrowth of key gut bacterial species believed to confer health benefits including to prevent recurrence of CDI
• Further analyses will be forthcoming Q1 2024, as data become available, regarding other endpoints from the Phase 2b trial, including Extended Clinical Cure (ECC) data up to 94 days
• Preparation underway for meetings with FDA, European Medicines Agency and other global regulatory agencies and advancement to international Phase 3 clinical trials
• Ibezapolstat has previously received FDA QIDP and Fast-Track Designation

https://www.prnewswire.com/news-releases/acurx-announces-positive-comparative-microbiology-and-microbiome-data-for-ibezapolstat-from-phase-2b-clinical-trial-in-cdi-patients-302036789.html